Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endometrial cancer
Pharma
Merck sees ‘pretty consistent’ data in sac-TMT’s 1st global ph. 3
The endometrial cancer data gave sac-TMT its first positive global phase 3 readout out of 18 trials that Merck has launched for the TROP2 ADC.
Angus Liu
Oct 26, 2026 11:30am
Karyopharm reports Xpovio miss, FDA filing in separate cancers
Jul 31, 2026 10:00am
Merck touts Keytruda front-line win in endometrial cancer subtype
Jul 15, 2026 3:33pm
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
In endometrial cancer, Merck and Kelun score with sac-TMT
May 18, 2026 11:21am
Merck's Keytruda turns in mixed results in gynecological cancers
Sep 13, 2024 6:05pm